Navigation Links
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Date:3/16/2008

w">http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential failure of Zevalin to prove safe and effective in further studies in combination with fludarabine and mitoxantrone for first-line treatment of untreated patients with follicular NHL or to be developed further in this combination for this indication, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling Zevalin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
2. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
3. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
4. Isolagen, Inc. Completes Enrollment in Isolagen Therapy(TM) Phase II/III Acne Scar Study
5. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
6. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
7. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. First Clinical Volumetric Modulated Arc Therapy Treatment Completed With Elekta Synergy(R) S at General Hospital Vienna
10. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
11. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Veran Medical Technologies, a ... the positive, cost-effective final results for the ... The SPiNPerc endobronchial percutaneous biopsy study results ... to biopsy when a traditional bronchoscopic method ... experience positive financial outcomes when more can ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... N.C., Jan. 19, 2011 As Pisgah Laboratories, Inc. ... it will soon begin scale-up of its patent-pending form ... of hydrocodone which imparts abuse deterrent properties to a ... clinical trials in their FDA / DEA registered facility. ...
... Medical Group Inc. (Nasdaq: WWIN ), ("Winner ... medical disposables and non-woven fabric made from 100% natural ... will participate in Arab Health 2011, to be held ... Exhibition Centre in Dubai, UAE. During ...
Cached Medicine Technology:Abuse Deterrent Hydrocodone / Acetaminophen Leads NDA Pipeline 2Abuse Deterrent Hydrocodone / Acetaminophen Leads NDA Pipeline 3Winner Medical to Participate in Arab Health 2011, International Healthcare Exhibition, in Dubai 2Winner Medical to Participate in Arab Health 2011, International Healthcare Exhibition, in Dubai 3
(Date:7/11/2014)... H.E.A.R Me Out Listens to Needs of ... to provide comprehensive information and services available to Colorado’s ... Coloradoans with hearing loss, this organization is the first ... the local and state resources that aims to give ... H.E.A.R. Me Out and its website was founded by ...
(Date:7/11/2014)... Having experienced mental illness from the perspectives ... hospital staff, Roger Grainger gives readers an intimate look at ... book, “You Never Get Out.” , According to the Mental ... will experience some kind of mental health problem in the ... take a look at the way mental illness is addressed ...
(Date:7/11/2014)... of personalized medicine may be just around the corner, ... Min Yu and scientists at Massachusetts General Hospital and ... in Science , Yu and her colleagues report ... blood streams of six patients. Some of these deadly ... to and establish secondary tumors in vital organs such ...
(Date:7/11/2014)... July 11, 2014 Cancer researchers in ... a significant impact on how patients respond to treatment ... mesothelioma. Surviving Mesothelioma has the full story. Click ... Researchers at the University of Ljubljana and the Ljubljana ... for different types of polymorphisms. They found that ...
(Date:7/11/2014)... Re-tearing a repaired knee Anterior Cruciate Ligament (ACL) ... presented today at the American Orthopaedic Society for Sports ... and patient education regarding modifiable risk factors may minimize ... “Our research suggests that a few risk factors such ... may point to the possibility of re-injury,” said lead ...
Breaking Medicine News(10 mins):Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 2Health News:H.E.A.R Me Out Listens to Needs of Hearing Impaired 3Health News:Psychiatric Hospital Patient and Registered Psychologist Explores Mental Health and Therapy in New Book "You Never Get Out" 2Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:New Study May Identify Risk Factors for ACL Re-injury 2
... general practitioners , who were free of dementia ... years and 3 years later by means of ... alcohol consumption and DSM-IV dementia diagnoses. Associations between ... alcohol (wine, beer, mixed alcohol beverages) and incident ...
... 7, 2011 Elsevier, the leading global publisher ... announced today it has begun offering Arabic bilingual editions ... the Middle East. The first order was recently received ... one of Elsevier,s many meant to help improve the ...
... , The U.S. spends around 2 billion dollars a ... large portion of this used for groundwater monitoring. Yet ... University,s Biodesign Institute, the information gathered is often of ... grant from the U.S. Department of Defense, Halden, assistant ...
... The 2011 Sleep in America poll released today by the National ... hour before bed. It also finds that a significant number of ... searching for ways to cope. , Many Americans report dissatisfaction ... 43% of Americans between the ages of 13 and 64 say ...
... heart disease, involving scientists from the University of ... of heart attacks. Professor Nilesh Samani, British ... Leicester, based at Glenfield Hospital, who co-led the international ... genes identified were not previously known to be involved ...
... Creating a healthy eating action plan and visualizing yourself carrying ... suggest. "Telling people to just change the way they ... study author Barbel Knauper, an associate professor of psychology at ... "But research has shown that if people make a ...
Cached Medicine News:Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 2Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 3Health News:Alcohol consumption after age 75 associated with lower risk of developing dementia 4Health News:Monitoring waste in groundwater (without all the waste) 2Health News:Sleepy connected Americans 2Health News:Sleepy connected Americans 3Health News:Sleepy connected Americans 4Health News:Sleepy connected Americans 5Health News:Sleepy connected Americans 6Health News:Leicester leads on heart attack genetic link discovery 2
... Merlin is a superior full-color, auto-focus, desktop ... user in mind, Merlin enables the user ... and white, high contrast positive or high ... magnifier, this optional feature enables the user ...
... general purpose incubators designed to ... and uniformity required for the ... versatile microprocessor controlled incubators feature ... easy-to-read digital display, and built-in ...
... Economy Incubators available in five different models. ... 1.4 cu. Ft. (39 liters), 2.5 cu. ... (129 liters. Equally important, Precision Economy Incubators ... temperature sensitivity, stability, and uniformity. As a ...
Aspheric diagnostic lens. 90D...
Medicine Products: